
ESSA Pharma Inc
NASDAQ:EPIX

ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
Country | Company | Market Cap | ROE | ||
---|---|---|---|---|---|
CA |
![]() |
ESSA Pharma Inc
NASDAQ:EPIX
|
71.5m USD |
-23%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
328B USD |
88%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
150.3B USD |
106%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
135.8B USD |
33%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD |
-6%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
119.8B AUD |
15%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65.3B USD |
16%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
519%
|
ESSA Pharma Inc
Glance View
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on ESSA Pharma Inc's most recent financial statements, the company has ROE of -23.1%.